Drugs / Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05794230 Background | Mar 2023 → Nov 2025 | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05794230 ↗ |
| Route | Oral | “Oral suspension - oral” NCT05794230 ↗ |